Monoclonal antibody treatments have not been tested in a pregnant population specifically and more data are needed in order to make a clear recommendation for this population. Currently, various monoclonal antibody treatments are available only under emergency use authorization (EUA) and recommended for the treatment of outpatients with mild to moderate COVID-19 who are at high risk of clinical progression as defined by the EUA criteria (NIH 2021). Pregnancy is now included among the conditions that put individuals at high risk for clinical progression, making patients with pregnancy as their only risk factor eligible to receive outpatient monoclonal antibodies, according to the EUA (NIH 2021). Obstetric care clinicians may consider the use of monoclonal antibodies for the treatment of non-hospitalized pregnant individuals, particularly if one or more additional risk factors are present (e.g. BMI ≥30, chronic kidney disease, diabetes, cardiovascular disease).